SLC5A2 and Hyperglycemia: To summarize, SGLT2 inhibitors not only downregulates SGLT2 but also decreases sodium uptake by NHE3, thus lowering both the reabsorption of sodium and glucose, with consequent improvement in fluid retention and hyperglycemia status and reestablishment of the tubular glomerular feedback.